ASF1B is an essential prognostic indicator linked to the growth and resistance characteristics of bladder cancer

Peng Zhang ¹, Peng Wang ², Yirong Wang ³

⁰Department of Urology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, China.

Tissue & Cell +

|

July 17, 2024

View abstract on PubMed

Summary

Anti-Silencing Function 1B Histone Chaperone (ASF1B) is highly expressed in bladder cancer (BC) and promotes tumor growth and cisplatin resistance. Inhibiting ASF1B significantly reduces BC cell proliferation, migration, and drug resistance in both in vitro and in vivo models.

Area Of Science

Oncology
Molecular Biology
Cancer Research

Background

Anti-silencing function 1 (ASF1) is a conserved histone chaperone.
ASF1B, a paralog of ASF1, plays a role in tumor metabolism and growth.
The regulatory network of ASF1B in cancer is not fully understood.

Purpose Of The Study

To investigate the biological role of ASF1B in bladder cancer (BC).
To explore the association between ASF1B expression and BC progression.

Main Methods

Analysis of ASF1B expression in BC using The Cancer Genome Atlas (TCGA) and Cancer Cell Line Encyclopedia (CCLE) databases.
Correlation analysis between BC pathway scores and ASF1B expression.
Experimental validation of ASF1B function in BC cells using Western blot, RT-PCR, cell proliferation assays, migration assays, and drug resistance studies (in vitro and in vivo).

Main Results

ASF1B is significantly overexpressed in BC tissues and cell lines.
ASF1B expression correlates with BC cell growth and DNA repair.
Inhibition of ASF1B suppressed BC cell proliferation, migration, and cisplatin resistance, both in vitro and in vivo.

Conclusions

ASF1B is a key regulator of BC cell proliferation, migration, and chemoresistance.
ASF1B represents a potential therapeutic target for bladder cancer treatment.
Targeting ASF1B may enhance the efficacy of cisplatin chemotherapy in BC.

Keywords:

ASF1B Bladder cancer Cell cycle Cell proliferation Tolerance